Evolent Health (EVH) EBITDA (2015 - 2026)

Evolent Health's EBITDA history runs 12 years deep, the most recent figure standing at -$10.6 million for Q1 2026.

• On a quarterly basis, EBITDA fell 553.45% year-over-year to -$10.6 million in Q1 2026; TTM through Mar 2026 was -$419.1 million, a 1360.43% decrease from a year earlier, with the FY2025 full-year figure at -$410.1 million, down 913.06% from the prior year.
• EBITDA rose to -$10.6 million in Q1 2026 per EVH's latest filing, from -$408.2 million in the prior quarter.
• Across five years, EBITDA topped out at $13.0 million in Q3 2022 and bottomed at -$408.2 million in Q4 2025.
• The 5-year median for EBITDA is -$10.4 million (2023), against an average of -$31.1 million.
• Across the five-year window, EBITDA jumped 296.79% in 2022 and tumbled 2095.26% in 2025, its largest moves.
• Year by year, EBITDA stood at -$1.9 million in 2022, then plunged by 1036.85% to -$21.3 million in 2023, then increased by 12.9% to -$18.6 million in 2024, then tumbled by 2095.26% to -$408.2 million in 2025, then soared by 97.4% to -$10.6 million in 2026.
• Per Business Quant, the three latest EVH EBITDA figures stand at -$10.6 million (Q1 2026), -$408.2 million (Q4 2025), and $886000.0 (Q3 2025).